CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a gene therapy using Vascular Endothelial Growth Factor to improve uterine blood flow in cases of fetal growth restriction. By enhancing blood supply, the project seeks to improve outcomes for severely affected fetuses and reduce the risks associated with preterm delivery.
Fetal growth restriction (FGR) globally occurs in 8% of pregnancies, is severe and early onset in 1:500 cases, affecting 11,000 babies annually in the EU.
In most cases, reduced uterine blood flow restricts substrate delivery to the fetus causing growth to slow or cease.
There is no treatment.
Currently the fetus is delivered very preterm before fetal death or irreversible organ damage occurs.
Affected neonates suffer intracranial haemorrhage, chronic lung disease, cerebral palsy, with heart dis…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, CHINNOR OXFORDSHIRE
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
UNIVERSITY OF EASTERN FINLAND (UEF)
Finland, KUOPIO
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Hamburg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
